CN104380110A - 处理血液、血液产品和器官的方法 - Google Patents

处理血液、血液产品和器官的方法 Download PDF

Info

Publication number
CN104380110A
CN104380110A CN201380018312.9A CN201380018312A CN104380110A CN 104380110 A CN104380110 A CN 104380110A CN 201380018312 A CN201380018312 A CN 201380018312A CN 104380110 A CN104380110 A CN 104380110A
Authority
CN
China
Prior art keywords
seq
idno
peptide
amyloid beta
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018312.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·威尔伯尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210102999 external-priority patent/DE102012102999A1/de
Priority claimed from DE102012108599.4A external-priority patent/DE102012108599B4/de
Priority claimed from DE102012108598.6A external-priority patent/DE102012108598A1/de
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Priority to CN201810884744.2A priority Critical patent/CN108926749A/zh
Publication of CN104380110A publication Critical patent/CN104380110A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
CN201380018312.9A 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法 Pending CN104380110A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810884744.2A CN108926749A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE102012102999.7 2012-04-05
DE201210102999 DE102012102999A1 (de) 2012-04-05 2012-04-05 Verfahren zur Behandlung von Blut, Blutprodukten und Organen
DE102012108599.4 2012-09-14
DE102012108598.6 2012-09-14
DE102012108599.4A DE102012108599B4 (de) 2012-09-14 2012-09-14 A-Beta-Oligomer-bindende Peptide und deren Verwendung
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
PCT/EP2013/057160 WO2013150126A2 (de) 2012-04-05 2013-04-05 Verfahren zur behandlung von blut, blutprodukten und organen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810884744.2A Division CN108926749A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法

Publications (1)

Publication Number Publication Date
CN104380110A true CN104380110A (zh) 2015-02-25

Family

ID=48184148

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380018312.9A Pending CN104380110A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法
CN201810884744.2A Pending CN108926749A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810884744.2A Pending CN108926749A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法

Country Status (8)

Country Link
US (3) US9591845B2 (https=)
EP (2) EP3260865B1 (https=)
JP (3) JP2015518474A (https=)
CN (2) CN104380110A (https=)
DK (2) DK2834643T3 (https=)
ES (2) ES2938886T3 (https=)
PL (1) PL3260865T3 (https=)
WO (1) WO2013150126A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745220A (zh) * 2013-09-26 2016-07-06 于利奇研究中心有限公司 结合β淀粉状蛋白的环状肽及其用途
CN107428811A (zh) * 2015-03-20 2017-12-01 于利奇研究中心有限公司 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A‑β‑物类的肽

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2834644B1 (de) 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DK2834643T3 (da) 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer
EP3747454B9 (de) 2013-09-26 2023-10-04 Priavoid GmbH Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz
WO2018009514A1 (en) * 2016-07-06 2018-01-11 George Stantchev Apparatus and method for plant extraction
JP7429343B2 (ja) 2018-01-05 2024-02-08 パス イーエックス，インク． 流体からの疾患材料の捕捉および除去のためのデバイス
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
JP7774972B2 (ja) * 2021-04-01 2025-11-25 禎弘 飯田 ペプチド結合切断活性を有する人工ペプチドおよびその利用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
CN1665838A (zh) * 2002-07-11 2005-09-07 瑞士联邦苏黎世技术大学 在蛋白质如病原性/传染性蛋白质中诱导构象转变的方法
CN101538329A (zh) * 2008-03-20 2009-09-23 中国医学科学院基础医学研究所 新的抗β-淀粉样多肽抗体的可变区序列及其编码序列
CN102224168A (zh) * 2008-11-19 2011-10-19 于利希研究中心有限公司 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物
CN102233128A (zh) * 2010-11-26 2011-11-09 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
WO2011137886A1 (de) * 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Mittel zur behandlung der alzheimerschen demenz

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5968820A (en) 1997-02-26 1999-10-19 The Cleveland Clinic Foundation Method for magnetically separating cells into fractionated flow streams
US6384105B1 (en) 1999-04-16 2002-05-07 William Marsh Rice University Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
ATE355374T1 (de) 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US20050158306A1 (en) 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102005009909A1 (de) 2005-03-01 2006-09-07 Heinrich-Heine-Universität Düsseldorf Verbindungen geeignet zur Beseitigung fehlgefalteter Proteine
DE102005031429A1 (de) 2005-07-04 2007-01-11 Heinrich-Heine-Universität Düsseldorf Verfahren zur selektiven Bestimmung pathologischer Proteinablagerungen
DE102005063175A1 (de) 2005-07-29 2007-02-01 Hans-Werner Prof. Dr. Heinrich Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung für Tiere, in der Biotechnologie (einschließlich der biologischen Forschung) und der medizinischen Diagnostik
US20070092508A1 (en) * 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
DE102006015140A1 (de) 2006-03-31 2007-10-11 Philipps-Universität Marburg Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen
JP2010521526A (ja) 2007-03-23 2010-06-24 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 多価ヘテロ二官能性ポリマーおよびその使用方法
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
DE102009037015A1 (de) 2009-08-07 2011-02-17 Michael Hajek Vorrichtung und Verfahren zur Eliminierung von bioschädlichen Stoffen aus Körperflüssigkeiten
DE102010017130B4 (de) * 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
EP2834644B1 (de) 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DK2834643T3 (da) * 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665838A (zh) * 2002-07-11 2005-09-07 瑞士联邦苏黎世技术大学 在蛋白质如病原性/传染性蛋白质中诱导构象转变的方法
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
CN101538329A (zh) * 2008-03-20 2009-09-23 中国医学科学院基础医学研究所 新的抗β-淀粉样多肽抗体的可变区序列及其编码序列
CN102224168A (zh) * 2008-11-19 2011-10-19 于利希研究中心有限公司 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物
WO2011137886A1 (de) * 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Mittel zur behandlung der alzheimerschen demenz
CN102233128A (zh) * 2010-11-26 2011-11-09 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIRK BARTNIK ET AL.: "Differently Selected d-Enantiomeric Peptides Act on Different Aβ Species", 《REJUVENATION RESEARCH》 *
GUOBAO ZHANG ET AL.: "Multiple-Peptide Conjugates for Binding β-Amyloid Plaques of Alzheimer′s Disease", 《BIOCONJUGATE CHEMISTRY》 *
OLUJIDE O. OLUBIYI ET AL.: "Structures of the Amyloid β-Peptides Aβ1−40 and Aβ1−42 as Influenced by pH and a D-Peptide", 《THE JOURNAL OF PHYSICAL CHEMISTRY》 *
刘明等: "Aβ寡聚体与阿尔采末病及其靶点药物研究进展", 《中国药理学报》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745220A (zh) * 2013-09-26 2016-07-06 于利奇研究中心有限公司 结合β淀粉状蛋白的环状肽及其用途
US10428127B2 (en) 2013-09-26 2019-10-01 Forschungszentrum Juelich Gmbh Cyclic, amyloid beta-binding peptides and the use thereof
CN105745220B (zh) * 2013-09-26 2020-03-27 于利奇研究中心有限公司 结合β淀粉状蛋白的环状肽及其用途
CN107428811A (zh) * 2015-03-20 2017-12-01 于利奇研究中心有限公司 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A‑β‑物类的肽
CN107428811B (zh) * 2015-03-20 2021-08-24 于利奇研究中心有限公司 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A-β-物类的肽

Also Published As

Publication number Publication date
EP2834643A2 (de) 2015-02-11
JP6619394B2 (ja) 2019-12-11
US20170172139A1 (en) 2017-06-22
US10772321B2 (en) 2020-09-15
JP2015518474A (ja) 2015-07-02
EP3260865A3 (de) 2018-05-09
US20150282477A1 (en) 2015-10-08
US9591845B2 (en) 2017-03-14
EP2834643B1 (de) 2019-10-23
ES2938886T3 (es) 2023-04-17
DK3260865T3 (da) 2023-02-27
ES2773125T3 (es) 2020-07-09
US20190037835A1 (en) 2019-02-07
US10123530B2 (en) 2018-11-13
JP2020037582A (ja) 2020-03-12
WO2013150126A2 (de) 2013-10-10
JP2017222682A (ja) 2017-12-21
WO2013150126A3 (de) 2014-01-03
PL3260865T3 (pl) 2023-04-11
EP3260865B1 (de) 2022-12-28
DK3260865T5 (da) 2024-10-14
JP6997160B2 (ja) 2022-02-03
CN108926749A (zh) 2018-12-04
DK2834643T3 (da) 2020-02-03
EP3260865A2 (de) 2017-12-27

Similar Documents

Publication Publication Date Title
JP6997160B2 (ja) 血液、血液生産物及び器官を処置する方法
CN104380111B (zh) 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
US10889618B2 (en) D-enantiomeric peptides derived from D3 and use thereof
JP2015518474A5 (https=)
JP2020023510A (ja) アミロイドベータ結合性環状ペプチドおよびその使用
CN105745219B (zh) 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途
JP6714610B2 (ja) アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド
DE102012102999A1 (de) Verfahren zur Behandlung von Blut, Blutprodukten und Organen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150225